Ankylosis progressive homolog upregulation inhibits cell viability and mineralization during fibroblast ossification by regulating the Wnt/β‑catenin signaling pathway
- Authors:
- Published online on: October 11, 2020 https://doi.org/10.3892/mmr.2020.11576
- Pages: 4551-4560
-
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Abstract
Introduction
The chronic progression of ankylosing spondylitis (AS) is characterized by inflammatory bone erosion, intravertebral bone loss and abnormal bone overgrowth (1,2). Sacroiliac joints, the vertebral column and ligaments affected by inflammation have been discovered to gradually cause extensive bone generation, leading to stiffness and fusion of the spine and syndesmophyte formation (3). Although previous studies have examined genetic and environmental factors, sex, age and ethnicity as causative factors, to the best of our knowledge, the etiology of AS remains unclear (3–5). Genetic factors underlying AS pathogenesis have been widely studied (6–8), and several genes that have been identified as susceptibility factors of AS may support the diagnosis of AS, such as HLA-B27, HLA-B51 and ERAP1 (5,9,10). In addition, genetic associations with AS may also provide insight into the etiopathogenesis of this disease (11). Although the molecular functions of several genes have been studied in the context of AS, their potential pathogenic role and their possible therapeutic use have not been evaluated (12).
Ankylosis progressive homolog (ANKH), an amino acid of 492 base pairs in length, is a multichannel transmembrane protein that transports intracellular pyrophosphate (PPi) to the extracellular milieu (13). Extracellular PPi was discovered to be a regulator of pathological calcification and a potential inhibitor of calcium phosphate mineralization (14–16). ANKH is the human homolog of the murine ANK gene (15). It has been demonstrated that the loss of ANK transporter function in mice led to excessive mineralization due to reduced PPi transport (17), which was later confirmed by other studies (18,19). Gurley et al (18) illustrated the role of ANK in PPi transport and suggested that ANKH mutations may cause skeletal diseases in humans. Ho et al (19) reported that ANK-deficient mice displayed increased PPi levels and presented with mineralization and skeletal ankylosis resembling AS. Thus, these previous studies indicated that ANK may regulate ectopic mineralization in animal models.
AS is characterized by pathological osteogenesis (20). Previous studies suggested that fibroblasts may be the target of heterotopic ossification because these cells belong to the same lineage as osteoblasts and were discovered to express osteogenesis-related genes, such as BMP2, osteocalcin and Runx2 (21,22). Fibroblasts are resident cells that preserve the extracellular matrix, both in healthy conditions and during inflammation (23). Thus, fibroblasts were suggested as likely contenders to be involved in osteogenesis (24). Fibroblasts and osteoblasts both originate from mesenchymal stem cell with overlapping phenotypes and through similar differentiation pathways, allowing fibroblasts to differentiate into osteoblasts and osteoblasts to differentiate into fibroblasts (25). In addition, the proliferative and osteogenic potential of fibroblasts was discovered to increase following the stimulation with fibronectin or BMP2 (26,27). Therefore, fibroblasts may serve as important mediators of osteogenesis.
The aim of the present study was to determine the function of ANKH in fibroblasts isolated from patients with AS. ANKH expression levels were analyzed in ligament tissue collected from patients with AS, and explored the effect of ANKH on the fibroblast cell viability, mineralization and ossification differentiation. From the results, it was hypothesized that the regulation of ANKH may affect fibroblast cell mineralization and ossification in AS.
Materials and methods
Patients and tissue samples
Ligament tissue samples were collected from four patients with AS (male; age, 18–42) and four patients with spinal fracture (JK) (male; age, 22–44) who attended The People's Hospital of Xinchang Hospital in March 2019 for treatment, according to the modified New York criteria (28). The patients used nonsteroidal anti-inflammatory drugs or disease-modifying anti-rheumatic drugs, but not anti-tumor necrosis factor. Written informed consent forms were signed by all patients. The study was approved by The Ethics Committees of the People's Hospital of Xinchang (Xinchang, China; approval no. XC201902114).
Cell culture
The ligaments samples from patients with AS and JK were separated in 60-mm sterile Petri dishes, and washed three times with D-Hank's balanced salt solution (HBSS; cat. no. 14170161; Gibco; Thermo Fisher Scientific, Inc.). The tissues were then sectioned into 1–3-mm3 blocks and washed with HBSS twice. The blocks were maintained in a 25-cm2 culture flask, with 4 mm space in between tissue blocks. Next, 2 ml high-glucose DMEM (cat. no. 11965118; Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (cat. no. A3160901; Gibco; Thermo Fisher Scientific, Inc.) was added to the flask. The flask was placed vertically inside an incubator at 37°C with 5% CO2 for 4 h. The bottle was gently laid flat at the end of this incubation, and the medium was changed every three days thereafter. After 4–8 days, when the cells reached 80% confluence, they were washed with HBSS and added to 1 ml 0.25% trypsin solution (cat. no. R001100; Gibco; Thermo Fisher Scientific, Inc.) at 37°C. After 2 min, 3 ml DMEM supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin and 10% FBS was immediately added to terminate cell dissociation. The cells were collected and centrifuged in a 15-ml centrifuge tube at 1,000 × g for 5 min at 4°C. The cell suspension was then divided (1:2) for secondary culture at 37°C with 5% CO2. The medium was changed every two days, and the cells were further subcultured in an incubator at 37°C with 5% CO2 whenever confluence reached 80–90%. Cells in the third generation were used for experimentation following examination of cell morphology under an inverted phase-contrast microscope (magnification, ×100; Chongqing UOP Photoelectric Technology Co., Ltd.).
Immunocytochemistry
Immunocytochemistry was performed to analyze the expression levels of vimentin in fibroblasts isolated from patients with AS and JK. Slides covered with fibroblast cells were washed with PBS three times for 5 min each time. After washing, 4% paraformaldehyde was added to each slide for 15 min at room temperature for fixed slides. Excess amounts of paraformaldehyde was removed, and the slices were then washed again with PBS three times for 5 min each time. Subsequently, 0.03% Triton X-100 was added to the slides for 25 min at room temperature and further incubated with 3% H2O2 for 10 min at room temperature. After blocking with 2% BSA (cat. no. 11021037; Gibco; Thermo Fisher Scientific, Inc.) for 30 min at room temperature. After washing with PBS three times for 5 min each time, the slides were then incubated with 50 µl anti-vimentin antibody (1:200; cat. no. ab193555; Abcam) overnight at 4°C. Following the primary antibody incubation, the slides were washed with PBS three times for 5 min each time, then incubated with 50 µl goat anti-rabbit IgG H&L (DyLight® 488) preabsorbed secondary antibody (1:100; cat. no. ab96899; Abcam) for 30 min at 37°C and then washed again with PBS three times. Staining was then visualized using a DAB staining kit (cat. no. E670033; Sangon Biotech Co., Ltd.) for 3–5 min at room temperature, and the slides were examined under an inverted phase-contrast microscope (magnification, ×400).
Cell transfection
The ANKH-pCMV6-XL5 overexpression plasmid (cat. no. SC120218) and empty vector negative control (NC; cat. no. PCMV6XL5) were purchased from OriGene Technologies, Inc. Fibroblasts from patients with AS were transfected with ANKH overexpression vector or NC. Fibroblasts from patients with JK were transfected with small interfering RNA (si) specific for ANKH (siANKH) or siNC, siANKH (5′-UCACUAUAAGCUAUCAGUGUG-3′) and siNC (5′-UUCUCCGAACGUGUCACGU-3′) were obtained from Guangzhou RiboBio Co., Ltd.
Fibroblasts were seeded into 24-well culture plates at a density of 2×104 cells/well one day before transfection and cultured to 90% confluence in 0.5 ml medium with 10% FBS without antibiotics. On the day of transfection, 20 pmol siANKH/siNC, or 2 µg ANKH/NC were separately diluted in 50 µl DMEM (cat. no. 12491015; Gibco; Thermo Fisher Scientific, Inc.). A volume of 1 µl Lipofectamine® 2000 (cat. no. 11668019; Invitrogen; Thermo Fisher Scientific, Inc.) was separately diluted in 50 µl DMEM and incubated at room temperature for 5 min. The diluted siANKH, siNC, ANKH or NC was then mixed with diluted Lipofectamine® 2000 and placed at room temperature for 20 min, then added to the cells. Finally, the cells were incubated at 37°C with 5% CO2 for 48 h, then harvested for subsequent experimentation. Untransfected cells also served as an additional control group.
Cell viability assay
Fibroblasts from patients with AS or JK were seeded into 96-well culture plates at 200 µl per well, then incubated for 1–6 days. Following the incubation, an MTT assay was used to detect cell viability. Briefly, 20 µl MTT (5 mg/ml; cat. no. M6494; Invitrogen; Thermo Fisher Scientific, Inc.) was added to the cells for 4 h at 37°C. After discarding the supernatant, 100 µl DMSO (cat. no. D12345; Invitrogen; Thermo Fisher Scientific, Inc.) was added to each well to dissolve the formazan crystals. The absorbance was measured at 490 nm at the initial timepoint, then every day over a time course of 6 days using a microplate reader. In a separate experiment, absorbance was read at 24, 48 and 72 h following transfection; the rest of the experimental details were unchanged.
Flow cytometric analysis of apoptosis
Apoptosis was analyzed using an Annexin V-FITC/propidium iodide (PI) staining kit (cat. no. V13242; Invitrogen; Thermo Fisher Scientific, Inc.). Fibroblasts (2×105 cells/well) were cultured in 6-well plates for 24 h at 37°C, then washed with cold PBS and centrifuged at 1,000 × g (5 min, 4°C). The cells were subsequently resuspended in 1X Annexin binding buffer, 5 µl Annexin V-FITC and 5 µl PI was added to the cells. The cells were incubated at room temperature for 15 min, then added to 400 µl 1X Annexin binding buffer. Cell apoptosis was assessed by flow cytometry using a FACScan instrument (BD Biosciences) equipped with CellQuest software (version 5.1; BD Biosciences). The apoptosis rate was calculated as the sum of early-apoptotic and late-apoptotic ell frequencies. Unstained cells, as well as Annexin V and PI single-stained cells were used as controls, and the gates for positive staining were set according to these controls.
Reverse transcription-quantitative PCR (RT-qPCR)
Relative ANKH mRNA expression levels were analyzed using RT-qPCR. Briefly, total RNA was extracted from fibroblasts using TRIzol® reagent (cat. no. 15596018; Invitrogen; Thermo Fisher Scientific, Inc.). RNA concentration was measured using a NanoDrop™ 8000 spectrophotometer (Thermo Fisher Scientific, Inc.). In addition, RNA integrity was confirmed by visualization of the fragments in 1.5% agarose gel electrophoresis (Invitrogen; Thermo Fisher Scientific, Inc.) followed by ethidium bromide and visualized under ultraviolet light.
RT into cDNA was performed using a PrimeScript RT Reagent kit with gDNA Eraser (cat. no. RR047A; Clontech Laboratories, Inc.). Briefly, 7 µl RNA, 1 µl gDNA Eraser and 2 µl 5X gDNA Eraser buffer were added into a reaction tube and incubated at 42°C for 2 min. The 10 µl sample was then mixed with 1 µl PrimeScript RT enzyme mix I, 1 µl RT primer mix, 4 µl 5X PrimeScript buffer II and 4 µl RNase-free distilled water. All samples were incubated at 37°C for 15 min and at 85°C for 5 sec, then allowed to cool down on ice. The resulting cDNA concentration and OD values were measured on a NanoDrop 8000 spectrophotometer. RT-qPCR was subsequently performed using a 7500 Real-Time PCR system (cat. no. 4351105; Applied Biosystems; Thermo Fisher Scientific, Inc.) with SYBR® Green PCR Master Mix (4312704, Thermo Fisher Scientific, Inc.). The thermocycling conditions consisted of an initial denaturation at 95°C for 10 min followed by 40 cycles at 94°C for 5 sec and 60°C for 1 min. The experiment was carried out three times. The relative expression levels of the mRNA was analyzed using the 2−ΔΔCq method (29), and ANKH expression was normalized to GAPDH. All primers used in in the present study were purchased from Sangon Biotech Co., Ltd. and the primer sequences are presented in Table I.
Alizarin Red staining
A 0.1% Alizarin Red dye liquor (pH 8.3) was prepared by dissolving 0.1 g Alizarin Red powder (cat. no. 130-22-3; Guidechem) in 100 ml Tris-HCl buffer (0.1 mol/l; cat. no. AP-9005-125; Thermo Fisher Scientific, Inc.). Fibroblasts isolated from the ligament tissue of patients with AS or JK (2×104 cells/well) were seeded into six-well plates. A cover glass was added to the 6-well plate before the cells were inoculated. When the cells reached ~50% confluence, the samples were collected, washed in PBS, then fixed in 4% methanol for 15 min at room temperature. The cells were then washed again with PBS three times for 3 min each time. Each cover glass was incubated with 0.1% Alizarin Red dye liquor for 30 min at 37°C, then washed using double steaming water three times for 3 min each time. The slides were examined under an optical microscope (magnification, ×400), and Alizarin Red staining absorbance was read at 510 nm for quantification.
Western blotting
Proteins were extracted from ligament tissue and fibroblast by using RIPA (cat. no. 89900; Thermo Fisher Scientific, Inc.). Protein concentration in the supernatant was measured using a Pierce™ BCA Protein assay kit (cat. no. 23225; Thermo Fisher Scientific, Inc.). A total of 20–40 µg protein lysate was separated by SDS-PAGE on 12% gels (cat. no. P0012A; Beyotime Institute of Biotechnology), then transferred onto PVDF membranes (cat. no. FFP28; Beyotime Institute of Biotechnology). The membranes were subsequently blocked using 5% non-fat milk in TBS containing 0.1% Tween 20 (cat. no. TA-999-TT; Thermo Fisher Scientific, Inc.) at room temperature for 1 h. The membranes were then incubated overnight at 4°C with the following primary antibodies: Anti-GADPH (cat. no. ab8245; 1:1,000; 36 kDa; Abcam), anti-ANKH (cat. no. ab90104; 1:1,000, 54 kDa; Abcam), anti-alkaline phosphatase (ALP; cat. no. ab83259; 1:1,000, 39 kDa; Abcam), anti-osteocalcin (OCN; cat. no. ab93876; 1:500; 11 kDa; Abcam), anti-Runt-related transcription factor 2 (Runx2; cat. no. ab23981; 1:1,000; 60 kDa; Abcam), anti-phosphorylated (p)-β-catenin (cat. no. 9561; 1:1,000, 92 kDa; Cell Signaling Technology, Inc.), anti-β-catenin (cat. no. 9562; 1:1,000, 92 kDa; Cell Signaling Technology, Inc.) and anti-c-Myc (cat. no. ab32072; 1:1,000; 57 kDa; Abcam). Following the primary antibody incubation, the membranes were incubated with a goat anti-rabbit IgG horseradish peroxidase-conjugated secondary antibody (cat. no. ab205718; 1:5,000, 42 kDa; Abcam) at room temperature for 1 h. Protein bands were visualized using an enhanced chemiluminescence reagent kit (cat. no. 345818; EMD Millipore). Protein expression levels were analyzed and normalized to GAPDH using ImageJ software (version 1.5, National Institutes of Health).
Statistical analysis
Statistical analysis was performed using SPSS 16.0 software (SPSS, Inc.) and data are presented as the mean ± SEM of three experiments. An unpaired Student's t-test was used to analyze statistical differences between two groups. Multi-group comparisons were performed using one-way ANOVA followed by a Tukey's post hoc test. P<0.05 was considered to indicate a statistically significant difference.
Results
ANKH expression levels in ligament tissue from patients with AS
The expression levels of ANKH were investigated in ligament tissues collected from patients with AS and JK controls (n=4/group) using western blot analysis. The results revealed that ANKH expression levels were significantly downregulated in the AS group compared with the JK group (P<0.001; Fig. 1A and B).
Fibroblast isolation and culture
Fibroblasts from the AS and JK groups were isolated from the ligament and cultured. The majority of the cells were shuttle-shaped and flat, with 2–3 protuberance, displaying the typical characteristics of fibroblasts (Fig. 1C). Notably, there were no observable differences in the morphology between the two groups. The intermediate filament protein vimentin is an important protein in mammalian fibroblasts (30). Fibroblasts from both groups were used for immunocytochemical staining of vimentin; the expression levels of vimentin in the AS and JK groups were positive (Fig. 1D).
Cell viability and apoptosis of fibroblasts
Cell viability and apoptosis were investigated in the fibroblasts from patients with AS and JK controls. The fibroblast viability in the AS group was significantly increased compared with the JK group (P<0.05 at days 1–3; P<0.001 at days 4–6; Fig. 1E). Moreover, the apoptotic rate, representing both early and late apoptosis, was significantly reduced in fibroblasts from patients with AS compared with the JK group (P<0.001; Fig. 1F).
ANKH overexpression inhibits AS fibroblast viability, mineralization and ossification
The effect of ANKH on cell viability, mineralization and ossification differentiation in AS was evaluated by transfecting ANKH overexpression vectors into fibroblasts from patients with AS and siANKH into fibroblasts from patients with JK. In the AS group, the relative ANKH mRNA expression levels were significantly upregulated following the transfection with the ANKH overexpression vector compared with the control and NC groups (P<0.001; Fig. 2A). By contrast, the transfection with siANKH in JK-derived fibroblasts significantly downregulated ANKH expression levels compared with the control and siNC group (P<0.001; Fig. 2B).
An MTT assay was performed to determine cell viability in both groups at 24, 48 and 72 h following transfection. Following transfection with the ANKH overexpression vector, the viability of fibroblasts in the AS group was significantly reduced compared with the control and siNC groups at each time point (P<0.05; Fig. 2D). However, the cell viability in the JK group was significantly increased, particularly 48 and 72 h after transfection, compared with the control group and the siNC group at each time point (P<0.05; Fig. 2D).
Moreover, Alizarin Red absorbance in ANKH-overexpressing fibroblasts from the AS group was significantly reduced compared with the control and NC groups (P<0.001; Fig. 2E and F). In comparison, Alizarin Red absorbance in the ANKH-silenced JK group was significantly increased compared with the siNC and control groups (P<0.001; Fig. 2G and H).
The expression levels of ossification markers were analyzed following transfection using western blotting analysis. ALP, OCN and Runx2 expression levels were significantly downregulated following ANKH overexpression in AS fibroblasts compared with the control and NC groups (P<0.001; Fig. 3A and B). By contrast, the expression levels of these ossification markers were significantly upregulated following siANKH silencing in JK fibroblasts compared with the control and siNC groups (P<0.001; Fig. 3C and D).
ANKH overexpression affects the Wnt/β-catenin signaling pathway in fibroblasts
The Wnt/β-catenin signaling pathway governs the differentiation of ossification and plays an important role in heterotopic ossification (25,31). The overexpression of ANKH significantly promoted β-catenin phosphorylation, whilst significantly downregulating the expression levels of β-catenin and c-Myc in AS fibroblasts compared with the control and NC groups (P<0.001; Fig. 3E and F). However, siANKH significantly upregulated the expression levels of β-catenin (P<0.05) and c-Myc (P<0.001), while inhibiting β-catenin phosphorylation (P<0.001) compared with the control and siNC groups in JK fibroblasts (Fig. 3G and H). In addition, the p-β-catenin/β-catenin ratios were significantly increased in the ANKH group compared with the untransfected control and NC groups in the AS-derived fibroblasts; however, the p-β-catenin/β-catenin ratio was significantly reduced in the siANKH group compared with the untransfected control and siNC groups in JK fibroblasts (P<0.001; Fig. 3I and J).
Discussion
The aim of the present study was to evaluate the role of ANKH in the ossification and mineralization of fibroblasts in patients with AS. The overexpression of the ANKH protein inhibited the viability and mineralization of fibroblasts in patients with AS. However, ANKH silencing led to the opposite effect, indicating a potential anti-osteogenic role for ANKH in AS.
The ANKH gene encodes a multi-channel transmembrane protein, which has a previously characterized role in genetic susceptibility to AS (32,33). A previous study suggested that ANKH did not significantly affect the susceptibility to or clinical manifestations of AS (32), which contradicted the results of another study (33), in which ANKH was associated with genetic susceptibility to AS in a sex-specific manner (33).
Previous studies have also evaluated the role of ANKH in heterotopic ossification (34,35). For instance, Gurley et al (34) demonstrated that the deletion of the ANK gene caused progressive mineralization and joint disease, leading to stiffness of the spine, a symptom similar to AS in humans. Moreover, loss of ANKH function resulted in pathological hydroxyapatite formation (35). Consistent with these previous studies, the present findings demonstrated that the expression levels of ANKH in ligaments from patients with AS were downregulated compared with the control subjects.
Moreover, the cellular morphology of fibroblasts from patients with AS and control subjects was also examined. Typical fibroblast cellular characteristics and positive vimentin expression confirmed that cultured cells isolated from the ligament retained a fibroblast phenotype. However, fibroblasts from patients with AS displayed increased viability and reduced apoptotic rates compared with the controls, indicating that AS pathogenesis may be related to fibroblast growth. This observation is consistent with a previous study, in which fibroblasts modulated osteoblast metabolism and osteogenesis (24). Therefore, it was hypothesized that inhibiting fibroblast viability or promoting apoptosis may prevent pathological osteogenesis in patients with AS.
In order to investigate the role of ANKH in fibroblast viability and differentiation, the effects of ANKH overexpression and silencing on fibroblasts were examined. The present findings demonstrated an association between ANKH expression levels and fibroblast viability and mineralization. ANKH overexpression in fibroblasts from patients with AS reduced cell viability and mineralization. Indeed, Alizarin Red staining indicated that the number of mineralized nodules was reduced following ANKH overexpression, suggesting a negative association between ANKH expression levels and fibroblast cell mineralization. Skubutyte et al (36) demonstrated that ANK prevented pathological mineralization. Similarly, Ho et al (19) revealed that the ANK gene prevented mineralization, whereas ANK deficiency accelerated mineralization in joints. Thus, it may be possible to reduce fibroblast mineralization through ANKH overexpression in order to prevent pathological bone formation.
The expression levels of osteogenic markers, such as ALP, OCN and Runx2, were analyzed to determine the levels of osteogenic differentiation and mineralization in fibroblasts from patients with AS. ALP is a phenotypic marker for early-stage osteoblast differentiation that serves a role in bone mineralization (37). In the present study, ANKH overexpression downregulated ALP expression levels in fibroblasts from patients with AS. This result was consistent with a previous study, which demonstrated that ANK was negatively associated with ALP expression levels in bone marrow stromal cells (38). OCN is a marker unique to osteoblasts and a late marker of osteoblast differentiation (38,39). In the present study, the expression levels of OCN and Runx2 were downregulated in ANKH-overexpressing cells. Runx2 can stimulate the transcription of osteoblast-related genes, such as those encoding OPN and OCN (40). Hill et al (41) also demonstrated that ANKH overexpression suppressed the mineralization and ossification of fibroblasts.
Wnt/β-catenin signaling induces mesenchymal stem cell differentiation, a precursor of osteoblastic activity (42). Day et al (43) suggested that Runx2 expression levels were possibly regulated by β-catenin upregulation. Conversely, the inhibition of Wnt signaling was illustrated to impair osteogenic differentiation in another previous study (44). β-catenin serves an important role in osteocyte viability, differentiation, proliferation and new bone formation (45,46). In fact, during the early and late stages of fracture repair, β-catenin activation is essential for osteoblast differentiation (45,46), and the loss of β-catenin resulted in increased bone resorption (47). The present findings were consistent with these aforementioned previous studies. Canonical Wnt/β-catenin signaling was reported to stimulate the proliferation and differentiation from fibroblasts to myofibroblast cell (48). In the present study, ANKH silencing reduced p-β-catenin expression levels, thereby offering a possible mechanism through which the cell viability and mineralization of normal fibroblasts were stimulated. However, ANKH overexpression in fibroblasts from patients with AS led to the opposite result. In addition, c-Myc is an important downstream target protein of the Wnt signaling pathway that can regulate proliferation, differentiation and apoptosis (49). Loveridge et al (50) reported that downregulated c-Myc protein levels prevented chondrocyte mineralization. In the present study, a negative association was identified between ANKH and c-Myc expression levels. Indeed, the overexpression of ANKH in fibroblasts from patients with AS downregulated the expression levels of c-Myc, resulting in reduced mineralization, whereas ANKH silencing in normal fibroblasts led to c-Myc upregulation. Thus, ANKH overexpression may reduce mineralization and ossification in AS through c-Myc downregulation and increased β-catenin phosphorylation and p-β-catenin/β-catenin, thereby inhibiting pathological bone formation.
However, there were some limitations to the present study. The immunofluorescence identification of JK fibroblasts by vimentin is also required. In addition, the positive effects of ANKH on AS fibroblasts was only determined in vitro; thus, the present findings should be further validated in vivo. Moreover, the potential use of the ANKH gene in clinical treatment also requires validation. Finally, although this preliminary study suggested that ANKH may regulate the Wnt/β-catenin pathway to inhibit the viability, mineralization and ossification of fibroblasts, the regulatory mechanism underlying this pathway requires further investigation.
In conclusion, the findings of the present study revealed the role of ANKH in fibroblasts isolated from the ligaments of patients with AS. The results discovered that ANKH expression levels were downregulated in ligaments of patients with AS. Moreover, fibroblasts from patients with AS displayed increased cell viability and reduced levels of apoptosis. ANKH overexpression was discovered to inhibit cell mineralization and ossification, which was likely mediated through its effect on ossification markers and the Wnt/β-catenin signaling pathway. Therefore, these results suggested that ANKH overexpression may prevent or delay new bone formation in AS.
Acknowledgements
Not applicable.
Funding
No funding was received.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Authors' contributions
XH designed the study. XH and YD acquired, analyzed and interpreted the data, drafted the manuscript and critically revised it for important intellectual content. XH and YD authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The present study was approved by The Ethics Committees of The People's Hospital of Xinchang (approval no. XC201902114). All procedures involving human participants were in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Written informed consent was provided by all patients.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Glossary
Abbreviations
Abbreviations:
ANKH |
ankylosis progressive homolog |
AS |
ankylosing spondylitis |
ALP |
alkaline phosphatase |
OCN |
osteocalcin |
Runx2 |
Runt-related transcription factor 2 |
RT-qPCR |
reverse transcription- quantitative PCR |
References
Smith JA: Update on ankylosing spondylitis: Current concepts in pathogenesis. Curr Allergy Asthma Rep. 15:4892015. View Article : Google Scholar : PubMed/NCBI | |
Leone A, Marino M, Dell'Atti C, Zecchi V, Magarelli N and Colosimo C: Spinal fractures in patients with ankylosing spondylitis. Rheumatol Int. 36:1335–1346. 2016. View Article : Google Scholar : PubMed/NCBI | |
Woodward LJ and Kam PC: Ankylosing spondylitis: Recent developments and anaesthetic implications. Anaesthesia. 64:540–548. 2009. View Article : Google Scholar : PubMed/NCBI | |
Brown MA and Wordsworth BP: Genetics in ankylosing spondylitis-current state of the art and translation into clinical outcomes. Best Pract Res Clin Rheumatol. 31:763–776. 2017. View Article : Google Scholar : PubMed/NCBI | |
Hanson A and Brown MA: Genetics and the causes of ankylosing spondylitis. Rheum Dis Clin North Am. 43:401–414. 2017. View Article : Google Scholar : PubMed/NCBI | |
Chen S, Li Y, Deng C, Li J, Wen X, Wu Z, Hu C, Zhang S, Li P, Zhang X, et al: The associations between PD-1, CTLA-4 gene polymorphisms and susceptibility to ankylosing spondylitis: A meta-analysis and systemic review. Rheumatol Int. 36:33–44. 2016. View Article : Google Scholar : PubMed/NCBI | |
Karami J, Mahmoudi M, Amirzargar A, Gharshasbi M, Jamshidi A, Aslani S and Nicknam MH: Promoter hypermethylation of BCL11B gene correlates with downregulation of gene transcription in ankylosing spondylitis patients. Genes Immun. 18:170–175. 2017. View Article : Google Scholar : PubMed/NCBI | |
Zhang P, Li Q, Qi J, Lv Q, Zheng X, Wu X and Gu J: Association between vitamin D receptor gene polymorphism and ankylosing spondylitis in Han Chinese. Int J Rheum Dis. 20:1510–1516. 2017. View Article : Google Scholar : PubMed/NCBI | |
Golder V and Schachna L: Ankylosing spondylitis: An update. Aust Fam Physician. 42:780–784. 2013.PubMed/NCBI | |
Wellcome Trust Case Control Consortium; Australo-Anglo- American Spondylitis Consortium (TASC), ; Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A, Kwiatkowski DP, McCarthy MI, et al: Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 39:1329–1337. 2007. View Article : Google Scholar : PubMed/NCBI | |
Brown MA, Kenna T and Wordsworth BP: Genetics of ankylosing spondylitis-insights into pathogenesis. Nat Rev Rheumatol. 12:81–91. 2016. View Article : Google Scholar : PubMed/NCBI | |
Ranganathan V, Gracey E, Brown MA, Inman RD and Haroon N: Pathogenesis of ankylosing spondylitis-recent advances and future directions. Nat Rev Rheumatol. 13:359–367. 2017. View Article : Google Scholar : PubMed/NCBI | |
Kirsch T, Kim HJ and Winkles JA: Progressive ankylosis gene (ank) regulates osteoblast differentiation. Cells Tissues Organs. 189:158–162. 2009. View Article : Google Scholar : PubMed/NCBI | |
Kanaujiya J, Bastow E, Luxmi R, Hao Z, Zattas D, Hochstrasser M, Reichenberger EJ and Chen IP: Rapid degradation of progressive ankylosis protein (ANKH) in craniometaphyseal dysplasia. Sci Rep. 8:157102018. View Article : Google Scholar : PubMed/NCBI | |
Mitton-Fitzgerald E, Gohr CM, Bettendorf B and Rosenthal AK: The role of ANK in calcium pyrophosphate deposition disease. Curr Rheumatol Rep. 18:252016. View Article : Google Scholar : PubMed/NCBI | |
Wang W, Xu J, Du B and Kirsch T: Role of the progressive ankylosis gene (ank) in cartilage mineralization. Mol Cell Biol. 25:312–323. 2005. View Article : Google Scholar : PubMed/NCBI | |
Williams CJ: The role of ANKH in pathologic mineralization of cartilage. Curr Opin Rheumatol. 28:145–151. 2016. View Article : Google Scholar : PubMed/NCBI | |
Gurley KA, Reimer RJ and Kingsley DM: Biochemical and genetic analysis of ANK in arthritis and bone disease. Am J Hum Genet. 79:1017–1029. 2006. View Article : Google Scholar : PubMed/NCBI | |
Ho AM, Johnson MD and Kingsley DM: Role of the mouse ank gene in control of tissue calcification and arthritis. Science. 289:265–270. 2000. View Article : Google Scholar : PubMed/NCBI | |
Qin X, Jiang T, Liu S, Tan J, Wu H, Zheng L and Zhao J: Effect of metformin on ossification and inflammation of fibroblasts in ankylosing spondylitis: An in vitro study. J Cell Biochem. 119:1074–1082. 2018. View Article : Google Scholar : PubMed/NCBI | |
Yu F, Cui Y, Zhou X, Zhang X and Han J: Osteogenic differentiation of human ligament fibroblasts induced by conditioned medium of osteoclast-like cells. Biosci Trends. 5:46–51. 2011. View Article : Google Scholar : PubMed/NCBI | |
Rutherford RB, Moalli M, Franceschi RT, Wang D, Gu K and Krebsbach PH: Bone morphogenetic protein-transduced human fibroblasts convert to osteoblasts and form bone in vivo. Tissue Eng. 8:441–452. 2002. View Article : Google Scholar : PubMed/NCBI | |
Turner JD, Naylor AJ, Buckley C, Filer A and Tak PP: Fibroblasts and osteoblasts in inflammation and bone damage. Adv Exp Med Biol. 1060:37–54. 2018. View Article : Google Scholar : PubMed/NCBI | |
da Costa Fernandes CJ, do Nascimento AS, da Silva RA and Zambuzzi WF: Fibroblast contributes for osteoblastic phenotype in a MAPK-ERK and sonic hedgehog signaling-independent manner. Mol Cell Biochem. 436:111–117. 2017. View Article : Google Scholar : PubMed/NCBI | |
Zou YC, Yang XW, Yuan SG, Zhang P, Ye YL and Li YK: Downregulation of dickkopf-1 enhances the proliferation and osteogenic potential of fibroblasts isolated from ankylosing spondylitis patients via the Wnt/β-catenin signaling pathway in vitro. Connect Tissue Res. 57:200–211. 2016. View Article : Google Scholar : PubMed/NCBI | |
Zhang WH, Li XL, Guo Y and Zhang Y: Proliferation and osteogenic activity of fibroblasts induced with fibronectin. Braz J Med Biol Res. 50:e62722017. View Article : Google Scholar : PubMed/NCBI | |
Chen F, Bi D, Cao G, Cheng C, Ma S, Liu Y and Cheng K: Bone morphogenetic protein 7-transduced human dermal-derived fibroblast cells differentiate into osteoblasts and form bone in vivo. Connect Tissue Res. 59:223–232. 2018.PubMed/NCBI | |
van der Linden S, Valkenburg HA and Cats A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 27:361–368. 1984. View Article : Google Scholar : PubMed/NCBI | |
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI | |
Turowski P, Myles T, Hemmings BA, Fernandez A and Lamb NJ: Vimentin dephosphorylation by protein phosphatase 2A is modulated by the targeting subunit B55. Mol Biol Cell. 10:1997–2015. 1999. View Article : Google Scholar : PubMed/NCBI | |
Tamamura Y, Otani T, Kanatani N, Koyama E, Kitagaki J, Komori T, Yamada Y, Costantini F, Wakisaka S, Pacifici M, et al: Developmental regulation of Wnt/beta-catenin signals is required for growth plate assembly, cartilage integrity, and endochondral ossification. J Biol Chem. 280:19185–19195. 2005. View Article : Google Scholar : PubMed/NCBI | |
Timms AE, Zhang Y, Bradbury L, Wordsworth BP and Brown MA: Investigation of the role of ANKH in ankylosing spondylitis. Arthritis Rheum. 48:2898–2902. 2003. View Article : Google Scholar : PubMed/NCBI | |
Tsui HW, Inman RD, Paterson AD, Reveille JD and Tsui FW: ANKH variants associated with ankylosing spondylitis: gender differences. Arthritis Res Ther. 7:R513–R525. 2005. View Article : Google Scholar : PubMed/NCBI | |
Gurley KA, Chen H, Guenther C, Nguyen ET, Rountree RB, Schoor M and Kingsley DM: Mineral formation in joints caused by complete or joint-specific loss of ANK function. J Bone Miner Res. 21:1238–1247. 2006. View Article : Google Scholar : PubMed/NCBI | |
Pendleton A, Johnson MD, Hughes A, Gurley KA, Ho AM, Doherty M, Dixey J, Gillet P, Loeuille D, McGrath R, et al: Mutations in ANKH cause chondrocalcinosis. Am J Hum Genet. 71:933–940. 2002. View Article : Google Scholar : PubMed/NCBI | |
Skubutyte R, Markova D, Freeman TA, Anderson DG, Dion AS, Williams CJ, Shapiro IM and Risbud MV: Hypoxia-inducible factor regulation of ANK expression in nucleus pulposus cells: Possible implications in controlling dystrophic mineralization in the intervertebral disc. Arthritis Rheum. 62:2707–2715. 2010. View Article : Google Scholar : PubMed/NCBI | |
Sharma U, Pal D and Prasad R: Alkaline phosphatase: An overview. Indian J Clin Biochem. 29:269–278. 2014. View Article : Google Scholar : PubMed/NCBI | |
Minashima T, Quirno M, Lee YJ and Kirsch T: The role of the progressive ankylosis protein (ANK) in adipogenic/osteogenic fate decision of precursor cells. Bone. 98:38–46. 2017. View Article : Google Scholar : PubMed/NCBI | |
Wei J and Karsenty G: An overview of the metabolic functions of osteocalcin. Rev Endocr Metab Disord. 16:93–98. 2015. View Article : Google Scholar : PubMed/NCBI | |
An S, Gao Y and Ling J: Characterization of human periodontal ligament cells cultured on three-dimensional biphasic calcium phosphate scaffolds in the presence and absence of L-ascorbic acid, dexamethasone and β-glycerophosphate in vitro. Exp Ther Med. 10:1387–1393. 2015. View Article : Google Scholar : PubMed/NCBI | |
Hill TP, Später D, Taketo MM, Birchmeier W and Hartmann C: Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell. 8:727–738. 2005. View Article : Google Scholar : PubMed/NCBI | |
Xu C, Wang J, Zhu T, Shen Y, Tang X, Fang L and Xu Y: Cross-talking between PPAR and WNT signaling and its regulation in mesenchymal stem cell differentiation. Curr Stem Cell Res Ther. 11:247–254. 2016. View Article : Google Scholar : PubMed/NCBI | |
Day TF, Guo X, Garrett-Beal L and Yang Y: Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell. 8:739–750. 2005. View Article : Google Scholar : PubMed/NCBI | |
Leucht P, Jiang J, Cheng D, Liu B, Dhamdhere G, Fang MY, Monica SD, Urena JJ, Cole W, Smith LR, et al: Wnt3a reestablishes osteogenic capacity to bone grafts from aged animals. J Bone Joint Surg Am. 95:1278–1288. 2013. View Article : Google Scholar : PubMed/NCBI | |
Duan P and Bonewald LF: The role of the wnt/β-catenin signaling pathway in formation and maintenance of bone and teeth. Int J Biochem Cell Biol. 77:23–29. 2016. View Article : Google Scholar : PubMed/NCBI | |
Chen Y, Whetstone HC, Lin AC, Nadesan P, Wei Q, Poon R and Alman BA: Beta-catenin signaling plays a disparate role in different phases of fracture repair: Implications for therapy to improve bone healing. PLoS Med. 4:e2492007. View Article : Google Scholar : PubMed/NCBI | |
Albers J, Keller J, Baranowsky A, Beil FT, Catala-Lehnen P, Schulze J, Amling M and Schinke T: Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin. J Cell Biol. 200:537–549. 2013. View Article : Google Scholar : PubMed/NCBI | |
Xu L, Cui WH, Zhou WC, Li DL, Li LC, Zhao P, Mo XT, Zhang Z and Gao J: Activation of Wnt/β-catenin signalling is required for TGF-β/Smad2/3 signalling during myofibroblast proliferation. J Cell Mol Med. 21:1545–1554. 2017. View Article : Google Scholar : PubMed/NCBI | |
Shi L, Wu YX, Yu JH, Chen X, Luo XJ and Yin YR: Research of the relationship between β-catenin and c-myc-mediated Wnt pathway and laterally spreading tumors occurrence. Eur Rev Med Pharmacol Sci. 21:252–257. 2017.PubMed/NCBI | |
Loveridge N, Farquharson C, Hesketh JE, Jakowlew SB, Whitehead CC and Thorp BH: The control of chondrocyte differentiation during endochondral bone growth in vivo: Changes in TGF-beta and the proto-oncogene c-myc. J Cell Sci. 105:949–956. 1993.PubMed/NCBI |